{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T04:47:01Z","timestamp":1780634821009,"version":"3.54.1"},"reference-count":133,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.cgh.2016.08.002","type":"journal-article","created":{"date-parts":[[2016,8,11]],"date-time":"2016-08-11T14:39:15Z","timestamp":1470926355000},"page":"972-985","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["New Pharmacologic Agents That Target Inflammation and Fibrosis in Nonalcoholic Steatohepatitis\u2013Related Kidney Disease"],"prefix":"10.1016","volume":"15","author":[{"given":"Giovanni","family":"Musso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"De Michieli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria","family":"Bongiovanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Parente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana","family":"Framarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Leone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara","family":"Berrutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Gambino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Cassader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solomon","family":"Cohney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Paschetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2016.08.002_bib1","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3109\/07853890.2010.518623","article-title":"Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity","volume":"43","author":"Musso","year":"2011","journal-title":"Ann Med"},{"key":"10.1016\/j.cgh.2016.08.002_bib2","doi-asserted-by":"crossref","first-page":"e1001680","DOI":"10.1371\/journal.pmed.1001680","article-title":"Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis","volume":"11","author":"Musso","year":"2014","journal-title":"PLoS Med"},{"key":"10.1016\/j.cgh.2016.08.002_bib3","first-page":"1282","article-title":"In female patients with NAFLD presence of type 2 diabetes and chronic kidney disease are independently associated with the risk of mortality","volume":"62","author":"Stepanova","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2016.08.002_bib4","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/TP.0000000000000945","article-title":"Nonalcoholic steatohepatitis is the most rapidly growing indication for simultaneous liver kidney transplantation in the United States","volume":"100","author":"Singal","year":"2016","journal-title":"Transplantation"},{"key":"10.1016\/j.cgh.2016.08.002_bib5","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s00125-011-2446-4","article-title":"Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials","volume":"55","author":"Musso","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.cgh.2016.08.002_bib6","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/S0140-6736(14)62459-4","article-title":"Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis","volume":"385","author":"Palmer","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2016.08.002_bib7","doi-asserted-by":"crossref","first-page":"18899","DOI":"10.1038\/srep18899","article-title":"Aliskiren reduces hepatic steatosis and epididymal fat mass and increases skeletal muscle insulin sensitivity in high-fat diet-fed mice","volume":"6","author":"Lee","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.cgh.2016.08.002_bib8","doi-asserted-by":"crossref","first-page":"e77817","DOI":"10.1371\/journal.pone.0077817","article-title":"Aliskiren attenuates steatohepatitis and increases turnover of hepatic fat in mice fed with a methionine and choline deficient diet","volume":"8","author":"Lee","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.cgh.2016.08.002_bib9","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.advms.2014.03.003","article-title":"Aliskiren attenuates oxidative stress and improves tubular status in non-diabetic patients with chronic kidney disease-placebo controlled, randomized, cross-over study","volume":"59","author":"Renke","year":"2014","journal-title":"Adv Med Sci"},{"key":"10.1016\/j.cgh.2016.08.002_bib10","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.peptides.2013.05.010","article-title":"Oral angiotensin-(1-7) prevented obesity and hepatic inflammation by inhibition of resistin\/TLR4\/MAPK\/NF-\u03baB in rats fed with high-fat diet","volume":"46","author":"Santos","year":"2013","journal-title":"Peptides"},{"key":"10.1016\/j.cgh.2016.08.002_bib11","doi-asserted-by":"crossref","first-page":"e0118758","DOI":"10.1371\/journal.pone.0118758","article-title":"Short-term treatment with diminazene aceturate ameliorates the reduction in kidney ACE2 activity in rats with subtotal nephrectomy","volume":"10","author":"Velkoska","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.cgh.2016.08.002_bib12","article-title":"Monocytic angiotensin-converting enzyme 2 relates to atherosclerosis in patients with chronic kidney disease","author":"Trojanowicz","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.cgh.2016.08.002_bib13","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1038\/mt.2015.92","article-title":"ACE2 therapy using adeno-associated viral vector inhibits liver fibrosis in mice","volume":"23","author":"Mak","year":"2015","journal-title":"Mol Ther"},{"key":"10.1016\/j.cgh.2016.08.002_bib14","doi-asserted-by":"crossref","first-page":"332","DOI":"10.2174\/0929866522666150209125401","article-title":"Angiotensin converting enzyme 2 activator DIZE modulates metabolic profile in mice decreasing lipogenesis","volume":"22","author":"de Mac\u00eado","year":"2015","journal-title":"Protein Pept Lett"},{"key":"10.1016\/j.cgh.2016.08.002_bib15","article-title":"Angiotensin-(1\u20137) improves non-alcoholic steatohepatitis via an adiponectin-independent mechanism","author":"Tang","year":"2016","journal-title":"Hepatol Res"},{"key":"10.1016\/j.cgh.2016.08.002_bib16","first-page":"1","article-title":"Targeting inflammation in diabetic kidney disease: early clinical trials","volume":"13","author":"Perez-Gomez","year":"2016","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.cgh.2016.08.002_bib17","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3748\/wjg.v20.i2.569","article-title":"Effects of pentoxifylline on nonalcoholic fatty liver disease: a meta-analysis","volume":"20","author":"Du","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.cgh.2016.08.002_bib18","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1681\/ASN.2014010012","article-title":"Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial","volume":"26","author":"Navarro-Gonzalez","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.cgh.2016.08.002_bib19","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.phrs.2016.03.001","article-title":"Effect of pentoxifylline on renal outcomes in chronic kidney disease patients: a systematic review and meta-analysis","volume":"107","author":"Leporini","year":"2016","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.cgh.2016.08.002_bib20","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.jpeds.2012.04.011","article-title":"The effect of cysteamine bitartrate on adiponectin multimerization in non-alcoholic fatty liver disease and healthy subjects","volume":"161","author":"Dohil","year":"2012","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.cgh.2016.08.002_bib21","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1681\/ASN.2012090962","article-title":"Cysteamine modulates oxidative stress and blocks myofibroblast activity in CKD","volume":"25","author":"Okamura","year":"2014","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.cgh.2016.08.002_bib22","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1053\/j.gastro.2016.08.027","article-title":"In children with nonalcoholic fatty liver disease, cysteamine bitartrate delayed release improves liver enzymes but does not reduce disease activity scores","volume":"151","author":"Schwimmer","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2016.08.002_bib23","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nm.3762","article-title":"Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development","volume":"21","author":"Kang","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.cgh.2016.08.002_bib24","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.metabol.2014.02.010","article-title":"Lipid accumulation is ahead of epithelial-to-mesenchymal transition and therapeutic intervention by acetyl-CoA carboxylase 2 silence in diabetic nephropathy","volume":"63","author":"Xu","year":"2014","journal-title":"Metabolism"},{"key":"10.1016\/j.cgh.2016.08.002_bib25","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1194\/jlr.P040501","article-title":"Altered renal lipid metabolism and renal lipid accumulation in human diabetic nephropathy","volume":"55","author":"Herman-Edelstein","year":"2014","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.cgh.2016.08.002_bib26","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nrd.2015.3","article-title":"Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies","volume":"15","author":"Musso","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.cgh.2016.08.002_bib27","doi-asserted-by":"crossref","DOI":"10.2337\/dc15-1182","article-title":"Fatty liver and chronic kidney disease: novel mechanistic insights and therapeutic opportunities","author":"Musso","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cgh.2016.08.002_bib28","doi-asserted-by":"crossref","first-page":"218","DOI":"10.2337\/dc11-1109","article-title":"Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study","volume":"35","author":"Ting","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cgh.2016.08.002_bib29","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3892\/ijmm.2015.2270","article-title":"Treatment with PPAR\u03b4 agonist alleviates non-alcoholic fatty liver disease by modulating glucose and fatty acid metabolic enzymes in a rat model","volume":"36","author":"Li","year":"2015","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.cgh.2016.08.002_bib30","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/hep.26461","article-title":"Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha\/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"58","author":"Staels","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2016.08.002_bib31","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.bcp.2012.10.014","article-title":"Reversal of the deleterious effects of chronic dietary HFCS-55 intake by PPAR-\u03b4 agonism correlates with impaired NLRP3 inflammasome activation","volume":"85","author":"Collino","year":"2013","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.cgh.2016.08.002_bib32","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.1093\/ndt\/gfs358","article-title":"Peroxisome proliferator-activated receptor-\u03b4 activation ameliorates albuminuria by\u00a0preventing nephrin loss and restoring podocyte integrity in\u00a0type 2 diabetes","volume":"27","author":"Lee","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.cgh.2016.08.002_bib33","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1210\/jc.2011-1061","article-title":"MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin","volume":"96","author":"Bays","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.cgh.2016.08.002_bib34","first-page":"1252A","article-title":"The hepatic and extrahepatic profile of resolution of steatohepatitis induced by GFT-505","volume":"62","author":"Sanyal","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2016.08.002_bib35","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1053\/j.ajkd.2009.11.013","article-title":"Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis","volume":"55","author":"Sarafidis","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.cgh.2016.08.002_bib36","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.2337\/dc13-2480","article-title":"Can a selective PPAR\u03b3 modulator improve glycemic control in patients with type 2 diabetes with fewer side effects compared with pioglitazone?","volume":"37","author":"DePaoli","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cgh.2016.08.002_bib37","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/clpt.2013.10","article-title":"Clinical proof-of-concept study with MSDC-0160, a prototype mTOT-modulating insulin sensitizer","volume":"93","author":"Colca","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cgh.2016.08.002_bib38","first-page":"A36","article-title":"Modulating mitochondrial pyruvate carrier activity decreases hepatic fibrosis in a mouse model of NASH","volume":"65","author":"McCommis","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.cgh.2016.08.002_bib39","first-page":"281A","article-title":"VL DRX-065, the stabilized R-enantiomer of pioglitazone is without PPARg agonist activity and exhibits the beneficial in\u00a0vivo pharmacodynamic effects for the treatment of NASH","volume":"62","author":"DeWitt","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2016.08.002_bib40","unstructured":"Mukul R. Saroglitazar shows therapeutic benefits in mouse model of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) (abstract 1957-P). American Diabetes Association 75th Scientific Sessions, June 5\u20139, 2015, Boston, MA."},{"key":"10.1016\/j.cgh.2016.08.002_bib41","unstructured":"Banshi D. To assess the effect of 4mg saroglitazar on patients of diabetes dyslipidemia with nonalcoholic fatty liver disease for 24 weeks at diabetes care CentreView session detail (abstract 712-P). American Diabetes Association 75th Scientific Sessions, June 5\u20139, 2015, Boston, MA."},{"key":"10.1016\/j.cgh.2016.08.002_bib42","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/1471-2369-15-180","article-title":"Effects of the dual peroxisome proliferator-activated receptor-\u03b1\/\u03b3 agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a phase IIb, randomized study","volume":"15","author":"Ruilope","year":"2014","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.cgh.2016.08.002_bib43","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1074\/jbc.M115.694323","article-title":"Farnesoid X receptor protects against kidney injury in uninephrectomized obese mice","volume":"291","author":"Gai","year":"2016","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.cgh.2016.08.002_bib44","doi-asserted-by":"crossref","first-page":"F1587","DOI":"10.1152\/ajprenal.00404.2009","article-title":"The farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria","volume":"297","author":"Wang","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.cgh.2016.08.002_bib45","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1124\/jpet.109.153510","article-title":"Coordinated regulation of dimethylarginine dimethylaminohydrolase-1 and cationic amino acid transporter-1 by farnesoid X receptor in mouse liver and kidney and its implication in the control of blood levels of asymmetric dimethylarginine","volume":"331","author":"Li","year":"2009","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.cgh.2016.08.002_bib46","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2016.08.002_bib47","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1002\/hep.27772","article-title":"Obeticholic acid and resveratrol in nonalcoholic fatty liver disease: all that is gold does not glitter, not all those who wander are lost","volume":"61","author":"Musso","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2016.08.002_bib48","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.gene.2016.01.039","article-title":"Role of microRNA 21 in diabetes and associated\/related diseases","volume":"582","author":"Sekar","year":"2016","journal-title":"Gene"},{"key":"10.1016\/j.cgh.2016.08.002_bib49","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/nature10112","article-title":"MicroRNAs 103 and 107 regulate insulin sensitivity","volume":"474","author":"Trajkovski","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.cgh.2016.08.002_bib50","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/ijo.2015.225","article-title":"Inhibition of mitochondrial \u03b2-oxidation by miR-107 promotes hepatic lipid accumulation and impairs glucose tolerance in\u00a0vivo","volume":"40","author":"Bhatia","year":"2016","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.cgh.2016.08.002_bib51","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.toxlet.2016.06.012","article-title":"MicroRNA-21 is associated with fibrosis in a rat model of nonalcoholic steatohepatitis and serves as a plasma biomarker for fibrotic liver disease","volume":"258","author":"Takeuchi-Yorimoto","year":"2016","journal-title":"Toxicol Lett"},{"key":"10.1016\/j.cgh.2016.08.002_bib52","doi-asserted-by":"crossref","first-page":"G298","DOI":"10.1152\/ajpgi.00346.2014","article-title":"Micro-RNA 21 inhibition of SMAD7 enhances fibrogenesis via leptin-mediated NADPH oxidase in experimental and human nonalcoholic steatohepatitis","volume":"308","author":"Dattaroy","year":"2015","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.cgh.2016.08.002_bib53","doi-asserted-by":"crossref","first-page":"121ra18","DOI":"10.1126\/scitranslmed.3003205","article-title":"MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways","volume":"4","author":"Chau","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.cgh.2016.08.002_bib54","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.bbrc.2014.01.065","article-title":"Inhibition of miRNA-21 prevents fibrogenic activation in podocytes and tubular cells in IgA nephropathy","volume":"444","author":"Bao","year":"2014","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.cgh.2016.08.002_bib55","article-title":"MicroRNA-21 is a potential link between non-alcoholic fatty liver disease and hepatocellular carcinoma via modulation of the HBP1-p53-Srebp1c pathway","author":"Wu","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2016.08.002_bib56","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.urolonc.2015.02.003","article-title":"microRNA-107 functions as a candidate tumor suppressor gene in renal clear cell carcinoma involving multiple genes","volume":"33","author":"Song","year":"2015","journal-title":"Urol Oncol"},{"key":"10.1016\/j.cgh.2016.08.002_bib57","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1007\/s00467-015-3297-x","article-title":"Heat shock proteins in the kidney","volume":"31","author":"Sreedharan","year":"2016","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.cgh.2016.08.002_bib58","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1194\/jlr.M048918","article-title":"Hsp90 modulates PPAR\u03b3 activity in a mouse model of nonalcoholic fatty liver disease","volume":"55","author":"Wheeler","year":"2014","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.cgh.2016.08.002_bib59","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.2337\/db14-1926","article-title":"Targeting HSP90 ameliorates nephropathy and atherosclerosis through suppression of NF-\u03baB and STAT signaling pathways in diabetic mice","volume":"64","author":"Lazaro","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.cgh.2016.08.002_bib60","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1038\/labinvest.2012.127","article-title":"Heat shock protein 90 inhibitor attenuates renal fibrosis through degradation of transforming growth factor-\u03b2 type II receptor","volume":"92","author":"Noh","year":"2012","journal-title":"Lab Invest"},{"key":"10.1016\/j.cgh.2016.08.002_bib61","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.pharep.2015.08.015","article-title":"The heat shock protein 90 inhibitor, 17-AAG, attenuates thioacetamide induced liver fibrosis in mice","volume":"68","author":"Abu-Elsaad","year":"2016","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.cgh.2016.08.002_bib62","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000108759","article-title":"Suppression of renal tubulointerstitial fibrosis by small interfering RNA targeting heat shock protein 47","volume":"28","author":"Xia","year":"2008","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.cgh.2016.08.002_bib63","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1089\/ars.2013.5619","article-title":"Role of NADPH oxidases in liver fibrosis","volume":"20","author":"Paik","year":"2014","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.cgh.2016.08.002_bib64","doi-asserted-by":"crossref","first-page":"285","DOI":"10.14348\/molcells.2015.0010","article-title":"Upstream regulators and downstream effectors of NADPH oxidases as novel therapeutic targets for diabetic kidney disease","volume":"38","author":"Gorin","year":"2015","journal-title":"Mol Cells"},{"key":"10.1016\/j.cgh.2016.08.002_bib65","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1681\/ASN.2013070810","article-title":"Genetic targeting or pharmacologic inhibition of NADPH oxidase nox4 provides renoprotection in long-term diabetic nephropathy","volume":"25","author":"Jha","year":"2014","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.cgh.2016.08.002_bib66","doi-asserted-by":"crossref","first-page":"e0129743","DOI":"10.1371\/journal.pone.0129743","article-title":"Deficiency of NOX1 or NOX4 prevents liver inflammation and fibrosis in mice through inhibition of hepatic stellate cell activation","volume":"10","author":"Lan","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.cgh.2016.08.002_bib67","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1002\/hep.25938","article-title":"Nicotinamide adenine dinucleotide phosphate oxidase in experimental liver fibrosis: GKT137831 as a novel potential therapeutic agent","volume":"56","author":"Aoyama","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2016.08.002_bib68","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1161\/CIRCRESAHA.112.267054","article-title":"Nox4 is a protective reactive oxygen species generating vascular NADPH oxidase","volume":"110","author":"Schroder","year":"2012","journal-title":"Circ Res"},{"key":"10.1016\/j.cgh.2016.08.002_bib69","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1517\/14728222.2014.896903","article-title":"Apoptosis signal-regulating kinase 1 as a therapeutic target","volume":"18","author":"Kawarazaki","year":"2014","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.cgh.2016.08.002_bib70","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1161\/HYPERTENSIONAHA.108.112292","article-title":"Olmesartan prevents cardiovascular injury and hepatic steatosis in obesity and diabetes, accompanied by apoptosis signal regulating kinase-1 inhibition","volume":"52","author":"Yamamoto","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.cgh.2016.08.002_bib71","doi-asserted-by":"crossref","first-page":"F1263","DOI":"10.1152\/ajprenal.00211.2014","article-title":"ASK1\/p38 signaling in renal tubular epithelial cells promotes renal fibrosis in the mouse obstructed kidney","volume":"307","author":"Ma","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.cgh.2016.08.002_bib72","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.2337\/db15-0384","article-title":"ASK1 inhibitor halts progression of diabetic nephropathy in Nos3-deficient mice","volume":"64","author":"Tesch","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.cgh.2016.08.002_bib73","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.3892\/mmr.2016.5393","article-title":"Deletion of Nrf2 leads to hepatic insulin resistance via the activation of NF-\u03baB in mice fed a high-fat diet","volume":"14","author":"Liu","year":"2016","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.cgh.2016.08.002_bib74","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1124\/mol.112.084269","article-title":"Nrf2 activators attenuate the progression of nonalcoholic steatohepatitis-related fibrosis in a dietary rat model","volume":"84","author":"Shimozono","year":"2013","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.cgh.2016.08.002_bib75","doi-asserted-by":"crossref","first-page":"12727","DOI":"10.3390\/molecules190812727","article-title":"Effect of redox modulating NRF2 activators on chronic kidney disease","volume":"19","author":"Choi","year":"2014","journal-title":"Molecules"},{"key":"10.1016\/j.cgh.2016.08.002_bib76","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/nep.12785","article-title":"The NLRP3 inflammasome in kidney disease and autoimmunity","volume":"21","author":"Hutton","year":"2016","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.cgh.2016.08.002_bib77","first-page":"235","article-title":"Blocking the NLRP3 inflammasome prevents inflammatory recruitment and fibrotic progression in experimental NASH","volume":"62","author":"Mridha","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2016.08.002_bib78","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4161\/cc.11.1.18559","article-title":"Bindarit: an anti-inflammatory small molecule that modulates the NFkappaB pathway","volume":"11","author":"Mora","year":"2012","journal-title":"Cell Cycle"},{"key":"10.1016\/j.cgh.2016.08.002_bib79","doi-asserted-by":"crossref","first-page":"G270","DOI":"10.1152\/ajpgi.00304.2014","article-title":"Hepatic TLR4 signaling in obese NAFLD","volume":"309","author":"Sharifnia","year":"2015","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.cgh.2016.08.002_bib80","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1124\/jpet.115.226860","article-title":"Inhibition of mitogen-activated protein kinases\/nuclear factor \u03baB-dependent inflammation by a novel chalcone protects the kidney from high fat diet-induced injuries in mice","volume":"355","author":"Fang","year":"2015","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.cgh.2016.08.002_bib81","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ijantimicag.2015.04.015","article-title":"In\u00a0vitro activity of solithromycin and its metabolites, CEM-214 and N-acetyl-CEM-101, against 100 clinical Ureaplasma spp. isolates compared with azithromycin","volume":"46","author":"Furfaro","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cgh.2016.08.002_bib82","first-page":"1301A","article-title":"Mechanism of action of the anti-NASH effects of solithromycin in a predictive NASH HCC mouse model","volume":"62","author":"Fernandes","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2016.08.002_bib83","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1124\/jpet.112.200733","article-title":"A\u00a0novel macrolide solithromycin exerts superior anti-inflammatory effect via NF-\u03baB inhibition","volume":"345","author":"Kobayashi","year":"2013","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.cgh.2016.08.002_bib84","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/hep.26783","article-title":"Pharmacological inhibition of the chemokine C-C motif chemokine ligand 2 (monocyte chemoattractant protein 1) accelerates liver fibrosis regression by suppressing Ly-6C(+) macrophage infiltration in mice","volume":"59","author":"Baeck","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2016.08.002_bib85","doi-asserted-by":"crossref","first-page":"e90883","DOI":"10.1371\/journal.pone.0090883","article-title":"Mesenchymal stem cells modulate albumin-induced renal tubular inflammation and fibrosis","volume":"9","author":"Wu","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.cgh.2016.08.002_bib86","doi-asserted-by":"crossref","first-page":"e0158156","DOI":"10.1371\/journal.pone.0158156","article-title":"Antifibrotic effects of the dual CCR2\/CCR5 antagonist cenicriviroc in animal models of liver and kidney fibrosis","volume":"11","author":"Lefebvre","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.cgh.2016.08.002_bib87","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S2213-8587(15)00261-2","article-title":"The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial","volume":"3","author":"de Zeeuw","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.cgh.2016.08.002_bib88","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/hep.26697","article-title":"Chemokine receptor CCR6-dependent accumulation of \u03b3\u03b4 T cells in injured liver restricts hepatic inflammation and fibrosis","volume":"59","author":"Hammerich","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2016.08.002_bib89","first-page":"1280A","article-title":"Improvement in hepatic steatosis in NASH in response to synbiotic supplementation","volume":"62","author":"Ferolla","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2016.08.002_bib90","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/1471-2369-15-106","article-title":"SYNbiotics Easing Renal failure by improving Gut microbiologY (SYNERGY): a protocol of placebo-controlled randomised cross-over trial","volume":"15","author":"Rossi","year":"2014","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.cgh.2016.08.002_bib91","first-page":"141","article-title":"Alleviation of insulin resistance and liver damage by oral administration of Imm124-E is mediated by increased Tregs and associated with increased serum GLP-1 and adiponectin: results of a phase I\/II clinical trial in NASH","volume":"5","author":"Mizrahi","year":"2012","journal-title":"J\u00a0Inflamm Res"},{"key":"10.1016\/j.cgh.2016.08.002_bib92","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1042\/CS20130267","article-title":"Role of Toll-like receptors in diabetic nephropathy","volume":"126","author":"Mudaliar","year":"2014","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.cgh.2016.08.002_bib93","first-page":"166A","article-title":"A\u00a0TLR4 antagonist decreases hepatic inflammation in response to endotoxin in fatty livers","volume":"22","author":"Oregui","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2016.08.002_bib94","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jhep.2015.08.038","article-title":"Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatophepatitis","volume":"64","author":"Armstrong","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2016.08.002_bib95","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jhep.2016.04.021","article-title":"Sitagliptin vs. placebo for non-alcoholic fatty liver disease: a randomized controlled trial","volume":"65","author":"Cui","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2016.08.002_bib96","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1007\/s00125-015-3618-4","article-title":"GIP increases adipose tissue expression and blood levels of MCP-1 in humans and links high energy diets to inflammation: a randomised trial","volume":"58","author":"G\u00f6gebakan","year":"2015","journal-title":"Diabetologia"},{"key":"10.1016\/j.cgh.2016.08.002_bib97","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.2337\/db13-1563","article-title":"Chronic reduction of GIP secretion alleviates obesity and insulin resistance under high-fat diet conditions","volume":"63","author":"Nasteska","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.cgh.2016.08.002_bib98","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1620\/tjem.231.57","article-title":"The glucagon-like peptide-1 receptor agonist, liraglutide, attenuates the progression of overt diabetic nephropathy in type 2 diabetic patients","volume":"231","author":"Imamura","year":"2013","journal-title":"Tohoku J Exp Med"},{"key":"10.1016\/j.cgh.2016.08.002_bib99","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.2337\/dc13-0323","article-title":"Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction","volume":"36","author":"Groop","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cgh.2016.08.002_bib100","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1210\/me.2015-1155","article-title":"Minireview: roles of fibroblast growth factors 19 and 21 in metabolic regulation and chronic diseases","volume":"29","author":"Zhang","year":"2015","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.cgh.2016.08.002_bib101","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.2337\/db07-0648","article-title":"FGFR4 prevents hyperlipidemia and insulin resistance but underlies high-fat diet induced fatty liver","volume":"56","author":"Huang","year":"2007","journal-title":"Diabetes"},{"key":"10.1016\/j.cgh.2016.08.002_bib102","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1210\/endo.143.5.8850","article-title":"Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity","volume":"143","author":"Tomlinson","year":"2002","journal-title":"Endocrinology"},{"key":"10.1016\/j.cgh.2016.08.002_bib103","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.clinbiochem.2012.03.019","article-title":"Preliminary evidence of a reduced serum level of fibroblast growth factor 19 in patients with biopsy-proven nonalcoholic fatty liver disease","volume":"45","author":"Eren","year":"2012","journal-title":"Clin Biochem"},{"key":"10.1016\/j.cgh.2016.08.002_bib104","doi-asserted-by":"crossref","first-page":"iv212","DOI":"10.1093\/ndt\/gft337","article-title":"Impaired postprandial fibroblast growth factor (FGF)-19 response in patients with stage 5 chronic kidney diseases is ameliorated following antioxidative therapy","volume":"28","author":"Li","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.cgh.2016.08.002_bib105","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1158\/0008-5472.CAN-14-0208","article-title":"Separating tumorigenicity from bile acid regulatory activity for endocrine hormone FGF19","volume":"74","author":"Zhou","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.cgh.2016.08.002_bib106","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s00702-011-0647-0","article-title":"Hepatic consequences of vascular adhesion protein-1 expression","volume":"118","author":"Weston","year":"2011","journal-title":"J\u00a0Neural Transm"},{"key":"10.1016\/j.cgh.2016.08.002_bib107","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1172\/JCI73722","article-title":"Vascular adhesion protein-1 promotes liver inflammation and drives hepatic fibrosis","volume":"125","author":"Weston","year":"2015","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.cgh.2016.08.002_bib108","doi-asserted-by":"crossref","first-page":"F908","DOI":"10.1152\/ajprenal.00698.2013","article-title":"Semicarbazide-sensitive amine oxidase (SSAO) inhibition ameliorates kidney fibrosis in a unilateral ureteral obstruction murine model","volume":"307","author":"Wong","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.cgh.2016.08.002_bib109","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/ki.2015.327","article-title":"Interstitial renal fibrosis due to multiple cisplatin treatments is ameliorated by semicarbazide-sensitive amine oxidase inhibition","volume":"89","author":"Katagiri","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.cgh.2016.08.002_bib110","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.jhep.2010.09.020","article-title":"Galectin-3 ablation protects mice from diet-induced NASH: a major scavenging role for galectin-3 in liver","volume":"54","author":"Iacobini","year":"2011","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2016.08.002_bib111","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/hep.26898","article-title":"Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma","volume":"59","author":"DePeralta","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2016.08.002_bib112","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1093\/ndt\/gfg603","article-title":"Galectin-3-positive cell infiltration in human diabetic nephropathy","volume":"19","author":"Kikuchi","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.cgh.2016.08.002_bib113","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jchf.2014.08.002","article-title":"The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries","volume":"3","author":"Calvier","year":"2015","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cgh.2016.08.002_bib114","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1681\/ASN.2012090909","article-title":"Elevated galectin-3 precedes the development of CKD","volume":"24","author":"O'Seaghdha","year":"2013","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.cgh.2016.08.002_bib115","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1681\/ASN.2014010093","article-title":"Galectin-3, renal function, and clinical outcomes: results from the LURIC and 4D studies","volume":"26","author":"Drechsler","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.cgh.2016.08.002_bib116","doi-asserted-by":"crossref","first-page":"F500","DOI":"10.1152\/ajprenal.00461.2014","article-title":"Pharmacological inhibition of galectin-3 protects against hypertensive nephropathy","volume":"308","author":"Frenay","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.cgh.2016.08.002_bib117","doi-asserted-by":"crossref","first-page":"e83481","DOI":"10.1371\/journal.pone.0083481","article-title":"Therapy of experimental NASH and fibrosis with galectin inhibitors","volume":"8","author":"Traber","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.cgh.2016.08.002_bib118","doi-asserted-by":"crossref","first-page":"e75361","DOI":"10.1371\/journal.pone.0075361","article-title":"Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease","volume":"8","author":"Traber","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.cgh.2016.08.002_bib119","first-page":"225A","article-title":"Early phase 1 clinical trial results of GR-MD-02, a galectin-3 inhibitor, in patients having non-alcoholic steatohepatitis (NASH) with advanced fibrosis (abstr 57). November 7-11, 2014; Boston, Massachusetts","volume":"60","author":"Harrison","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2016.08.002_bib120","doi-asserted-by":"crossref","first-page":"e57915","DOI":"10.1371\/journal.pone.0057915","article-title":"Increased adiposity, dysregulated glucose metabolism and systemic inflammation in galectin-3 KO mice","volume":"8","author":"Pang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.cgh.2016.08.002_bib121","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/bcp.12196","article-title":"Rho kinase inhibition in diabetic kidney disease","volume":"76","author":"Komers","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.cgh.2016.08.002_bib122","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1053\/j.gastro.2015.12.037","article-title":"Lipid-induced signaling causes release of inflammatory extracellular vesicles from hepatocytes","volume":"150","author":"Hirsova","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2016.08.002_bib123","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3760\/cma.j.issn.0366-6999.20131917","article-title":"Fasudil hydrochloride hydrate, a rho-kinase inhibitor, ameliorates hepatic fibrosis in rats with type 2 diabetes","volume":"127","author":"Zhou","year":"2014","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.cgh.2016.08.002_bib124","doi-asserted-by":"crossref","first-page":"20304","DOI":"10.1038\/srep20304","article-title":"ROCK1 induces endothelial-to-mesenchymal transition in glomeruli to aggravate albuminuria in diabetic nephropathy","volume":"6","author":"Peng","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.cgh.2016.08.002_bib125","doi-asserted-by":"crossref","first-page":"8010","DOI":"10.3892\/mmr.2015.4467","article-title":"Inhibitory effects of fasudil on renal interstitial fibrosis induced by unilateral ureteral obstruction","volume":"12","author":"Baba","year":"2015","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.cgh.2016.08.002_bib126","doi-asserted-by":"crossref","first-page":"16814","DOI":"10.1073\/pnas.1414189111","article-title":"Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism","volume":"111","author":"Zanin-Zhorov","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cgh.2016.08.002_bib127","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.celrep.2015.01.050","article-title":"ROCK-isoform-specific polarization of macrophages associated with age-related macular degeneration","volume":"10","author":"Zandi","year":"2015","journal-title":"Cell Rep"},{"key":"10.1016\/j.cgh.2016.08.002_bib128","doi-asserted-by":"crossref","first-page":"300","DOI":"10.3389\/fphar.2015.00300","article-title":"New insight into the anti-liver fibrosis effect of multitargeted tyrosine kinase inhibitors: from molecular target to clinical trials","volume":"6","author":"Qu","year":"2016","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.cgh.2016.08.002_bib129","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/hep.26898","article-title":"Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma","volume":"59","author":"Fuchs","year":"2014","journal-title":"Hepatology"},{"issue":"Suppl 4","key":"10.1016\/j.cgh.2016.08.002_bib130","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/kisup.2014.13","article-title":"EGFR signaling in renal fibrosis","author":"Zhuang","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.cgh.2016.08.002_bib131","doi-asserted-by":"crossref","first-page":"316ra193","DOI":"10.1126\/scitranslmed.aac7071","article-title":"Tissue transcriptome-driven identification of epidermal growth factor as a chronic kidney disease biomarker","volume":"7","author":"Ju","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.cgh.2016.08.002_bib132","first-page":"359","article-title":"Epidermal growth factor receptor inhibition with erlotinib ameliorates anti-Thy 1.1-induced experimental glomerulonephritis","volume":"29","author":"Rintala","year":"2016","journal-title":"J\u00a0Nephrol"},{"key":"10.1016\/j.cgh.2016.08.002_bib133","doi-asserted-by":"crossref","first-page":"645727","DOI":"10.1155\/2015\/645727","article-title":"Plumbagin ameliorates CCl 4-induced hepatic fibrosis in rats via the epidermal growth factor receptor signaling pathway","volume":"2015","author":"Chen","year":"2015","journal-title":"Evid Based Complement Alternat Med"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356516305110?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356516305110?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:22:11Z","timestamp":1761542531000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356516305110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":133,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S1542356516305110"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2016.08.002","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New Pharmacologic Agents That Target Inflammation and Fibrosis in Nonalcoholic Steatohepatitis\u2013Related Kidney Disease","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2016.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 by the AGA Institute","name":"copyright","label":"Copyright"}]}}